Biomarkers for Efficacy and Toxicity
1 clinical trials · Condition
◉ Watch Biomarkers for Efficacy and Toxicity
| Record | Firm | Date |
|---|---|---|
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab (NCT03919539) | Peking University People's Hospital | 2019-12-01 |
Track Biomarkers for Efficacy and Toxicity automatically
Every clearance here is in the API, with alerts when new ones post.